Stem cells may supercharge CAR t for tough blood cancers
Disease control
Recruiting now
This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …
Phase: PHASE1 • Sponsor: Joshua Sasine, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC